Michael Kerrigan PhD U.S. FDA

Michael Kerrigan graduated from Saint Joseph’s University, Philadelphia, PA, with a B.S. in Chemistry. Mike then moved to the University of Pennsylvania, also Philadelphia, to study organic and organometallic chemistry, receiving a Ph.D. in Chemistry in 2008. In 2008, Mike became a chemistry, manufacturing, and controls (CMC) reviewer on the Chemotherapeutics Team in the Division of Manufacturing Technologies (DMT) of the Office of New Animal Drug Evaluation (ONADE) within the Center for Veterinary Medicine (CVM) at the United States Food and Drug Administration (FDA), where he primarily reviewed quality changes to oral dosage animal drugs and drug substance manufacturing information found in Type II DMFs and VMFs. In July 2018, Mike represented CVM on the steering committee and as a presenter at the United States Pharmacopoeia (USP)/Generic Animal Drug Alliance (GADA) Workshop “Understanding Veterinary Active Pharmaceutical Ingredients (APIs): A Guide to Navigating Regulatory and Pharmacopeial Standards.” Since 2018, Mike has been a supervisory chemist and leader of the Drug Substance Team 1 (renamed in 2022 from the Drug Substance Matrix Team) in DMT.